Cycloserine microbiology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cycloserine}} {{CMG}} ; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GM...")
 
No edit summary
Line 4: Line 4:




==MICROBIOLOGY==


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2 | publisher =  | date =  | accessdate  }}</ref>
Cycloserine inhibits cell–wall synthesis in susceptible strains of gram–positive and gram–negative bacteria and in Mycobacterium tuberculosis.
Susceptibility Tests
 
Cycloserine clinical laboratory standard powder is available for both direct and indirect methods1 of determining the susceptibility of strains of mycobacteria. Cycloserine MICs for susceptible strains are 25 μg/mL or lower.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2 | publisher =  | date =  | accessdate  }}</ref>





Revision as of 16:48, 26 December 2013

Cycloserine
SEROMYCIN ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]


MICROBIOLOGY

Cycloserine inhibits cell–wall synthesis in susceptible strains of gram–positive and gram–negative bacteria and in Mycobacterium tuberculosis. Susceptibility Tests

Cycloserine clinical laboratory standard powder is available for both direct and indirect methods1 of determining the susceptibility of strains of mycobacteria. Cycloserine MICs for susceptible strains are 25 μg/mL or lower.[1]


References

  1. "SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER]". Text " accessdate " ignored (help)

Adapted from the FDA Package Insert.